Department Of Gastroenterology 2
51. A second update on mapping the human genetic architecture of COVID-19
52. A second update on mapping the human genetic architecture of COVID-19
53. Case series of complex therapy of hemoblastosis in the context of COVID-19
54. A global action agenda for turning the tide on fatty liver disease
55. A global action agenda for turning the tide on fatty liver disease
56. A global action agenda for turning the tide on fatty liver disease
57. A global action agenda for turning the tide on fatty liver disease
58. A global action agenda for turning the tide on fatty liver disease
59. A global action agenda for turning the tide on fatty liver disease
60. A global action agenda for turning the tide on fatty liver disease
61. A global action agenda for turning the tide on fatty liver disease
62. A global action agenda for turning the tide on fatty liver disease
63. A global action agenda for turning the tide on fatty liver disease
64. Advancing the global public health agenda for NAFLD: a consensus statement
65. Advancing the global public health agenda for NAFLD: a consensus statement
66. Advancing the global public health agenda for NAFLD: a consensus statement
67. Advancing the global public health agenda for NAFLD: a consensus statement
68. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
69. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
70. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
71. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
72. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
73. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
74. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
75. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
76. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
77. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
78. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
79. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
80. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
81. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study
82. Burden of disease scenarios by state in the USA, 2022–50: a forecasting analysis for the Global Burden of Disease Study 2021
83. The burden of diseases, injuries, and risk factors by state in the USA, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
84. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
85. Assessment of cognitive impairment in patients with chronic viral hepatitis
86. CHRONIC FATIGUE IN PATIENTS WITH CHRONIC VIRAL HEPATITIS
87. Factors Affecting Health-related Quality of Life in Patients with Chronic Viral Hepatitis in Kazakhstan
88. Quality of life assessment in chronic viral hepatitis
89. The Neuropsychiatric Aspect of the Chronic Viral Hepatitis
90. VIRAL HEPATITIS B AND C AND NEUROLOGICAL IMPAIRMENT
91. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
92. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
93. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
94. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
95. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
96. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
97. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
98. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
99. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
100. The case for simplifying and using absolute targets for viral hepatitis elimination goals
1 2 3